{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:59:34Z","timestamp":1791305974186,"version":"4.3.1"},"reference-count":131,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","endo.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.ecl.2015.03.001","type":"journal-article","created":{"date-parts":[[2015,5,30]],"date-time":"2015-05-30T07:00:19Z","timestamp":1432969219000},"page":"411-434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Adrenocortical Carcinoma"],"prefix":"10.1016","volume":"44","author":[{"given":"Eric","family":"Baudin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ecl.2015.03.001_bib1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00000478-198403000-00001","article-title":"Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors","volume":"8","author":"Weiss","year":"1984","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1016\/j.ecl.2015.03.001_bib2","doi-asserted-by":"crossref","first-page":"E161","DOI":"10.1210\/jc.2010-0653","article-title":"High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors","volume":"95","author":"Sbiera","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2015.03.001_bib3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1677\/erc.1.01029","article-title":"Management of patients with adrenal cancer: recommendations of an international consensus conference","volume":"12","author":"Schteingart","year":"2005","journal-title":"Endocr Relat Cancer"},{"issue":"Suppl 7","key":"10.1016\/j.ecl.2015.03.001_bib4","doi-asserted-by":"crossref","first-page":"vii131","DOI":"10.1093\/annonc\/mds231","article-title":"Adrenal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Berruti","year":"2012","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ecl.2015.03.001_bib5","first-page":"663","article-title":"Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms","volume":"6","author":"Goldblum","year":"1993","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.ecl.2015.03.001_bib6","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0090-4295(00)00852-9","article-title":"Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors","volume":"57","author":"Terzolo","year":"2001","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.ecl.2015.03.001_bib7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00129039-200109000-00004","article-title":"Value of topoisomerase II alpha, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2\/neu immunohistochemical expression for the prediction of biologic behavior in adrenocortical neoplasms","volume":"9","author":"Gupta","year":"2001","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"12","key":"10.1016\/j.ecl.2015.03.001_bib8","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1097\/00000478-200212000-00009","article-title":"Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors","volume":"26","author":"Aubert","year":"2002","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.ecl.2015.03.001_bib9","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1200\/JCO.20.4.941","article-title":"Adrenocortical carcinoma: clinical, morphologic, and molecular characterization","volume":"20","author":"Stojadinovic","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.ecl.2015.03.001_bib10","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/BF02067349","article-title":"Adrenal cortical carcinoma in Norway, 1970-1984","volume":"16","author":"S\u00f8reide","year":"1992","journal-title":"World J Surg"},{"issue":"5","key":"10.1016\/j.ecl.2015.03.001_bib11","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s00268-005-0329-x","article-title":"Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?","volume":"30","author":"Kebebew","year":"2006","journal-title":"World J Surg"},{"issue":"11","key":"10.1016\/j.ecl.2015.03.001_bib12","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1016\/j.ejca.2013.02.034","article-title":"Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993","volume":"49","author":"Kerkhofs","year":"2013","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ecl.2015.03.001_bib13","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr Rev"},{"issue":"7","key":"10.1016\/j.ecl.2015.03.001_bib14","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1210\/jc.2005-2730","article-title":"Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients","volume":"91","author":"Abiven","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2015.03.001_bib15","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1210\/jc.2014-3182","article-title":"Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection","volume":"100","author":"Beuschlein","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2015.03.001_bib16","unstructured":"Lib\u00e9 R. Prognostic factors for synchronous stage III and IV adrenocortical carcinomas (ACC): an ENSAT study. 2015."},{"issue":"2","key":"10.1016\/j.ecl.2015.03.001_bib17","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1210\/jc.2013-2856","article-title":"Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma","volume":"99","author":"Else","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2015.03.001_bib18","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1530\/EJE-13-0519","article-title":"Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center","volume":"169","author":"Ayala-Ramirez","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.ecl.2015.03.001_bib19","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.eururo.2013.11.006","article-title":"Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer","volume":"65","author":"Berruti","year":"2014","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.ecl.2015.03.001_bib20","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1210\/jc.2011-1565","article-title":"Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors","volume":"96","author":"Arlt","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.ecl.2015.03.001_bib21","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00268-001-0047-y","article-title":"Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group","volume":"25","author":"Icard","year":"2001","journal-title":"World J Surg"},{"issue":"2","key":"10.1016\/j.ecl.2015.03.001_bib22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/cncr.24030","article-title":"Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification","volume":"115","author":"Fassnacht","year":"2009","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ecl.2015.03.001_bib23","first-page":"805","article-title":"Effects of increased cross-sectional imaging on the diagnosis and prognosis of adrenocortical carcinoma: analysis of the National Cancer Database","volume":"186","author":"Kutikov","year":"2011","journal-title":"J\u00a0Urol"},{"issue":"6","key":"10.1016\/j.ecl.2015.03.001_bib24","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.surg.2012.08.024","article-title":"Resection of adrenocortical carcinoma is less complete and local recurrence occurs sooner and more often after laparoscopic adrenalectomy than after open adrenalectomy","volume":"152","author":"Miller","year":"2012","journal-title":"Surgery"},{"key":"10.1016\/j.ecl.2015.03.001_bib25","article-title":"First prognostic analysis of stage iii adrenocortical carcinoma patients after complete resection: a retrospective French multicentric study from the INCA-COMETE network","author":"Do Cao","year":"2011","journal-title":"European Congress of Endocrinology"},{"issue":"2","key":"10.1016\/j.ecl.2015.03.001_bib26","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/SLA.0b013e3182367ac3","article-title":"Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma","volume":"255","author":"Reibetanz","year":"2012","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.ecl.2015.03.001_bib27","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1210\/jc.2006-0706","article-title":"Prognostic parameters of metastatic adrenocortical carcinoma","volume":"92","author":"Assi\u00e9","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"23","key":"10.1016\/j.ecl.2015.03.001_bib28","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ecl.2015.03.001_bib29","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1002\/cncr.23886","article-title":"Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors","volume":"113","author":"Bilimoria","year":"2008","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ecl.2015.03.001_bib30","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.surg.2007.09.006","article-title":"Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma","volume":"142","author":"Gonzalez","year":"2007","journal-title":"Surgery"},{"issue":"6","key":"10.1016\/j.ecl.2015.03.001_bib31","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.surg.2013.06.033","article-title":"Operative intervention for recurrent adrenocortical cancer","volume":"154","author":"Dy","year":"2013","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.ecl.2015.03.001_bib32","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1210\/jc.2012-2559","article-title":"The role of surgery in the management of recurrent adrenocortical carcinoma","volume":"98","author":"Erdogan","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2015.03.001_bib33","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s12672-011-0091-5","article-title":"FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma","volume":"2","author":"Deandreis","year":"2011","journal-title":"Horm Cancer"},{"issue":"11","key":"10.1016\/j.ecl.2015.03.001_bib34","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1007\/s00259-014-2834-3","article-title":"Impact of 18F-FDG PET\/CT on the management of adrenocortical carcinoma: analysis of 106 patients","volume":"41","author":"Takeuchi","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.ecl.2015.03.001_bib35","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.2953","article-title":"Integrated genomic characterization of adrenocortical carcinoma","volume":"46","author":"Assi\u00e9","year":"2014","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.ecl.2015.03.001_bib36","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1158\/1078-0432.CCR-08-1067","article-title":"Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling","volume":"15","author":"Giordano","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ecl.2015.03.001_bib37","doi-asserted-by":"crossref","first-page":"E174","DOI":"10.1210\/jc.2012-2993","article-title":"Identification of a CpG island methylator phenotype in adrenocortical carcinomas","volume":"98","author":"Barreau","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ecl.2015.03.001_bib38","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.humpath.2014.04.005","article-title":"MicroRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations","volume":"45","author":"Duregon","year":"2014","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1016\/j.ecl.2015.03.001_bib39","doi-asserted-by":"crossref","first-page":"E493","DOI":"10.1210\/jc.2014-3282","article-title":"Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma","volume":"100","author":"Juhlin","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ecl.2015.03.001_bib40","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10434-999-0719-7","article-title":"Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma","volume":"6","author":"Schulick","year":"1999","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.ecl.2015.03.001_bib41","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ejca.2009.12.007","article-title":"The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the International Union Against Cancer-staging system: a North American validation","volume":"46","author":"Lughezzani","year":"2010","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ecl.2015.03.001_bib42","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.surg.2014.08.018","article-title":"A\u00a0novel staging system for adrenocortical carcinoma better predicts survival in patients with stage I\/II disease","volume":"156","author":"Asare","year":"2014","journal-title":"Surgery"},{"issue":"6","key":"10.1016\/j.ecl.2015.03.001_bib43","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.surg.2010.09.024","article-title":"Adrenocortical carcinoma: the influence of large vessel extension","volume":"148","author":"Turbendian","year":"2010","journal-title":"Surgery"},{"issue":"2","key":"10.1016\/j.ecl.2015.03.001_bib44","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00423-011-0876-6","article-title":"Outcome of operation in patients with adrenocortical cancer invading the inferior vena cava\u2013a European Society of Endocrine Surgeons (ESES) survey","volume":"397","author":"Mihai","year":"2012","journal-title":"Langenbecks Arch Surg"},{"issue":"7","key":"10.1016\/j.ecl.2015.03.001_bib45","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00423-010-0698-y","article-title":"Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade","volume":"395","author":"Miller","year":"2010","journal-title":"Langenbecks Arch Surg"},{"issue":"23","key":"10.1016\/j.ecl.2015.03.001_bib46","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1200\/JCO.2009.27.5958","article-title":"Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel","volume":"28","author":"Berruti","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.ecl.2015.03.001_bib47","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2559.2009.03423.x","article-title":"Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification","volume":"55","author":"Volante","year":"2009","journal-title":"Histopathology"},{"issue":"50","key":"10.1016\/j.ecl.2015.03.001_bib48","first-page":"885","article-title":"Deficits in the management of patients with adrenocortical carcinoma in Germany","volume":"107","author":"Johanssen","year":"2010","journal-title":"Dtsch Arztebl Int"},{"issue":"7","key":"10.1016\/j.ecl.2015.03.001_bib49","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1200\/JCO.2008.18.5678","article-title":"Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival","volume":"27","author":"De Reyni\u00e8s","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.ecl.2015.03.001_bib50","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S0039-6060(97)90229-4","article-title":"Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma","volume":"122","author":"Bellantone","year":"1997","journal-title":"Surgery"},{"issue":"8","key":"10.1016\/j.ecl.2015.03.001_bib51","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1245\/s10434-012-2358-7","article-title":"Resection of adrenocortical carcinoma liver metastasis: is it justified?","volume":"19","author":"Gaujoux","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.ecl.2015.03.001_bib52","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/jso.23015","article-title":"Operative management for recurrent and metastatic adrenocortical carcinoma","volume":"105","author":"Datrice","year":"2012","journal-title":"J\u00a0Surg Oncol"},{"issue":"21","key":"10.1016\/j.ecl.2015.03.001_bib53","doi-asserted-by":"crossref","first-page":"8276","DOI":"10.1158\/0008-5472.CAN-10-2014","article-title":"Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers","volume":"70","author":"Ragazzon","year":"2010","journal-title":"Cancer Res"},{"issue":"27","key":"10.1016\/j.ecl.2015.03.001_bib54","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1200\/JCO.2008.17.2775","article-title":"Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma","volume":"27","author":"Veytsman","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.ecl.2015.03.001_bib55","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1517\/14728210903413522","article-title":"Drugs in the medical treatment of Cushing\u2019s syndrome","volume":"14","author":"Schteingart","year":"2009","journal-title":"Expert Opin Emerg Drugs"},{"issue":"6","key":"10.1016\/j.ecl.2015.03.001_bib56","doi-asserted-by":"crossref","first-page":"R205","DOI":"10.1530\/ERC-12-0191","article-title":"New developments in the medical treatment of Cushing\u2019s syndrome","volume":"19","author":"Van der Pas","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"10.1016\/j.ecl.2015.03.001_bib57","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1210\/jc.2011-0536","article-title":"Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing\u2019s syndrome","volume":"96","author":"Kamenick\u00fd","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.ecl.2015.03.001_bib58","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1007\/s00464-013-3169-z","article-title":"SAGES guidelines for minimally invasive treatment of adrenal pathology","volume":"27","author":"Stefanidis","year":"2013","journal-title":"Surg Endosc"},{"issue":"8","key":"10.1016\/j.ecl.2015.03.001_bib59","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00268-002-6666-0","article-title":"Results of laparoscopic adrenalectomy for large and potentially malignant tumors","volume":"26","author":"Henry","year":"2002","journal-title":"World J Surg"},{"issue":"4","key":"10.1016\/j.ecl.2015.03.001_bib60","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.eururo.2010.06.024","article-title":"Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients","volume":"58","author":"Brix","year":"2010","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ecl.2015.03.001_bib61","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.eururo.2010.01.036","article-title":"Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer","volume":"57","author":"Porpiglia","year":"2010","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ecl.2015.03.001_bib62","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.surg.2008.08.025","article-title":"Endoscopic adrenalectomy: is there an optimal operative approach? Results of a single-center case-control study","volume":"144","author":"Lombardi","year":"2008","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.ecl.2015.03.001_bib63","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1245\/s10434-013-3164-6","article-title":"Long-term survival after adrenalectomy for stage I\/II adrenocortical carcinoma (ACC): a retrospective comparative cohort study of laparoscopic versus open approach","volume":"21","author":"Donatini","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.ecl.2015.03.001_bib64","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1530\/EJE-09-1096","article-title":"Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis?","volume":"162","author":"Leboulleux","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"10.1016\/j.ecl.2015.03.001_bib65","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1007\/s00464-013-3034-0","article-title":"Does laparoscopic adrenalectomy jeopardize oncologic outcomes for patients with adrenocortical carcinoma?","volume":"27","author":"Cooper","year":"2013","journal-title":"Surg Endosc"},{"issue":"1","key":"10.1016\/j.ecl.2015.03.001_bib66","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.surg.2012.02.005","article-title":"Surgery in adrenocortical carcinoma: importance of national cooperation and centralized surgery","volume":"152","author":"Hermsen","year":"2012","journal-title":"Surgery"},{"issue":"11","key":"10.1016\/j.ecl.2015.03.001_bib67","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1245\/s10434-014-3931-z","article-title":"Treatment patterns and outcomes for patients with adrenocortical carcinoma associated with hospital case volume in the United States","volume":"21","author":"Gratian","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ecl.2015.03.001_bib68","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.surg.2005.05.014","article-title":"Adrenocortical carcinoma extending into the inferior vena cava: presentation of a 15-patient series and review of the literature","volume":"139","author":"Chiche","year":"2006","journal-title":"Surgery"},{"issue":"3","key":"10.1016\/j.ecl.2015.03.001_bib69","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/ejcts\/ezt408","article-title":"Surgical management of malignant tumours invading the inferior vena cava","volume":"45","author":"Fabre","year":"2014","journal-title":"Eur J Cardiothorac Surg"},{"issue":"3","key":"10.1016\/j.ecl.2015.03.001_bib70","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1677\/erc.1.01025","article-title":"Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial","volume":"12","author":"Berruti","year":"2005","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.ecl.2015.03.001_bib71","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1677\/ERC-09-0341","article-title":"Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma (ACC)","volume":"17","author":"Malandrino","year":"2010","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"10.1016\/j.ecl.2015.03.001_bib72","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s00330-014-3202-1","article-title":"Thermal ablation techniques: a curative treatment of bone metastases in selected patients?","volume":"24","author":"Deschamps","year":"2014","journal-title":"Eur Radiol"},{"issue":"7","key":"10.1016\/j.ecl.2015.03.001_bib73","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1245\/s10434-011-1564-z","article-title":"Liver resection and ablation for metastatic adrenocortical carcinoma","volume":"18","author":"Ripley","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ecl.2015.03.001_bib74","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/cncr.11084","article-title":"Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases","volume":"97","author":"Wood","year":"2003","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ecl.2015.03.001_bib75","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jvir.2010.05.020","article-title":"Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma","volume":"21","author":"Cazejust","year":"2010","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"11","key":"10.1016\/j.ecl.2015.03.001_bib76","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1210\/jc.2006-1007","article-title":"Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma","volume":"91","author":"Fassnacht","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ecl.2015.03.001_bib77","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.ijrobp.2010.04.030","article-title":"Adjuvant and definitive radiotherapy for adrenocortical carcinoma","volume":"80","author":"Sabolch","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ecl.2015.03.001_bib78","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1210\/jc.2012-2367","article-title":"A\u00a0retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma","volume":"98","author":"Habra","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ecl.2015.03.001_bib79","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/PPO.0b013e31829e3221","article-title":"Role of radiotherapy in adrenocortical carcinoma","volume":"19","author":"Ho","year":"2013","journal-title":"Cancer J"},{"issue":"3","key":"10.1016\/j.ecl.2015.03.001_bib80","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-12-0368","article-title":"Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells","volume":"20","author":"Hescot","year":"2013","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.ecl.2015.03.001_bib81","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/1097-0142(19890801)64:3<765::AID-CNCR2820640333>3.0.CO;2-I","article-title":"Adrenal cortical carcinoma","volume":"64","author":"Venkatesh","year":"1989","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.ecl.2015.03.001_bib82","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJM199004263221705","article-title":"Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy","volume":"322","author":"Luton","year":"1990","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ecl.2015.03.001_bib83","first-page":"1006","article-title":"Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma","volume":"110","author":"Decker","year":"1991","journal-title":"Surgery"},{"issue":"6","key":"10.1016\/j.ecl.2015.03.001_bib84","first-page":"963","article-title":"An eleven-year experience with adrenocortical carcinoma","volume":"112","author":"Pommier","year":"1992","journal-title":"Surgery"},{"issue":"5","key":"10.1016\/j.ecl.2015.03.001_bib85","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/bjc.1994.183","article-title":"Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients","volume":"69","author":"Haak","year":"1994","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.ecl.2015.03.001_bib86","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1159\/000227608","article-title":"Adrenocortical carcinoma: experience in 45 patients","volume":"54","author":"Barzon","year":"1997","journal-title":"Oncology"},{"issue":"5","key":"10.1016\/j.ecl.2015.03.001_bib87","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1159::AID-CNCR28>3.0.CO;2-R","article-title":"Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study","volume":"88","author":"Williamson","year":"2000","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ecl.2015.03.001_bib88","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2","article-title":"Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p\u2019DDD) levels on the treatment of patients with adrenocortical carcinoma","volume":"92","author":"Baudin","year":"2001","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ecl.2015.03.001_bib89","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1530\/EJE-10-0956","article-title":"Mitotane has a strong and a durable inducing effect on CYP3A4 activity","volume":"164","author":"Van Erp","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"10.1016\/j.ecl.2015.03.001_bib90","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1210\/jc.2012-1419","article-title":"Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial","volume":"97","author":"Kroiss","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ecl.2015.03.001_bib91","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1677\/ERC-08-0103","article-title":"Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly","volume":"15","author":"Daffara","year":"2008","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"10.1016\/j.ecl.2015.03.001_bib92","first-page":"257","article-title":"The Cleveland Clinic experience with adrenal cortical carcinoma","volume":"141","author":"Bodie","year":"1989","journal-title":"J\u00a0Urol"},{"issue":"23","key":"10.1016\/j.ecl.2015.03.001_bib93","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","author":"Terzolo","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ecl.2015.03.001_bib94","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1245\/s10434-009-0716-x","article-title":"Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane","volume":"17","author":"Grubbs","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ecl.2015.03.001_bib95","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1530\/EJE-13-0242","article-title":"Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection","volume":"169","author":"Terzolo","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.ecl.2015.03.001_bib96","first-page":"377","article-title":"CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma","volume":"67","author":"Van Slooten","year":"1983","journal-title":"Cancer Treat Rep"},{"issue":"1","key":"10.1016\/j.ecl.2015.03.001_bib97","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.1993.11.1.161","article-title":"Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study","volume":"11","author":"Bukowski","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.ecl.2015.03.001_bib98","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1023\/A:1008377915129","article-title":"Streptozocin and o,p\u2019DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use","volume":"11","author":"Khan","year":"2000","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ecl.2015.03.001_bib99","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1002\/1097-0142(19910615)67:12<2997::AID-CNCR2820671211>3.0.CO;2-#","article-title":"5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma","volume":"67","author":"Schlumberger","year":"1991","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ecl.2015.03.001_bib100","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/bjc.1998.530","article-title":"Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma","volume":"78","author":"Bonacci","year":"1998","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.ecl.2015.03.001_bib101","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1002\/cncr.10487","article-title":"A\u00a0phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist","volume":"94","author":"Abraham","year":"2002","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ecl.2015.03.001_bib102","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/bjc.2013.229","article-title":"Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study","volume":"108","author":"Urup","year":"2013","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ecl.2015.03.001_bib103","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1385\/MO:21:2:167","article-title":"Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer","volume":"21","author":"Khan","year":"2004","journal-title":"Med Oncol"},{"issue":"2","key":"10.1016\/j.ecl.2015.03.001_bib104","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1677\/ERC-09-0281","article-title":"Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-\/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study","volume":"17","author":"Sperone","year":"2010","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"10.1016\/j.ecl.2015.03.001_bib105","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/annonc\/mdf291","article-title":"Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma","volume":"13","author":"Baudin","year":"2002","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ecl.2015.03.001_bib106","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1158\/1078-0432.CCR-14-0265","article-title":"Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors","volume":"21","author":"Jones","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ecl.2015.03.001_bib107","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s12672-014-0182-1","article-title":"The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent\/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial","volume":"5","author":"Lerario","year":"2014","journal-title":"Horm Cancer"},{"issue":"4","key":"10.1016\/j.ecl.2015.03.001_bib108","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00280-009-1083-9","article-title":"Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma","volume":"65","author":"Haluska","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ecl.2015.03.001_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ecl.2015.03.001_bib110","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/bjc.2013.46","article-title":"Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma","volume":"108","author":"Naing","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ecl.2015.03.001_bib111","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.15527","article-title":"A phase II trial of gefinitinib monotherapy in patients with unresectable adrenocortical carcinoma","author":"Samnotra","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ecl.2015.03.001_bib112","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1210\/jc.2007-2564","article-title":"Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine","volume":"93","author":"Quinkler","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2015.03.001_bib113","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1677\/erc.1.01124","article-title":"The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R","volume":"13","author":"Gross","year":"2006","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.ecl.2015.03.001_bib114","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12020-013-9878-1","article-title":"Everolimus therapy for progressive adrenocortical cancer","volume":"44","author":"Fraenkel","year":"2013","journal-title":"Endocrine"},{"issue":"4","key":"10.1016\/j.ecl.2015.03.001_bib115","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1210\/jc.2013-2298","article-title":"The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer","volume":"99","author":"O\u2019Sullivan","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2015.03.001_bib116","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1530\/EJE-09-0804","article-title":"Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma","volume":"162","author":"Wortmann","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2015.03.001_bib117","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/EJE-11-0918","article-title":"Phase II study of weekly paclitaxel and sorafenib as second\/third-line therapy in patients with adrenocortical carcinoma","volume":"166","author":"Berruti","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ecl.2015.03.001_bib118","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1186\/1471-2407-14-561","article-title":"A\u00a0phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers","volume":"14","author":"Halperin","year":"2014","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.ecl.2015.03.001_bib119","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1210\/jc.2010-2676","article-title":"Plasma concentrations of o,p\u2019DDD, o,p\u2019DDA, and o,p\u2019DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENSAT multicenter study","volume":"96","author":"Hermsen","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2015.03.001_bib120","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1677\/ERC-09-0190","article-title":"The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane","volume":"17","author":"W\u00e4ngberg","year":"2010","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"10.1016\/j.ecl.2015.03.001_bib121","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1530\/EJE-11-0557","article-title":"High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up","volume":"166","author":"Maucl\u00e8re-Denost","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"10.1016\/j.ecl.2015.03.001_bib122","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1210\/jc.2013-2281","article-title":"Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma","volume":"98","author":"Kerkhofs","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2015.03.001_bib123","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1677\/ERC-08-0224","article-title":"Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy","volume":"16","author":"Ronchi","year":"2009","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"10.1016\/j.ecl.2015.03.001_bib124","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1158\/1078-0432.CCR-11-2692","article-title":"Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer","volume":"18","author":"Volante","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ecl.2015.03.001_bib125","doi-asserted-by":"crossref","first-page":"e105855","DOI":"10.1371\/journal.pone.0105855","article-title":"CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma","volume":"9","author":"Ronchi","year":"2014","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/j.ecl.2015.03.001_bib126","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1210\/jc.2013-1396","article-title":"Detection of circulating tumor cells in patients with adrenocortical carcinoma: a monocentric preliminary study","volume":"98","author":"Pinzani","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2015.03.001_bib127","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1210\/jc.2012-3310","article-title":"Adrenocortical cancer and IGF2: is the game over or our experimental models limited?","volume":"98","author":"Drelon","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1-2","key":"10.1016\/j.ecl.2015.03.001_bib128","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.mce.2010.11.014","article-title":"The Wnt\/beta-catenin pathway in adrenocortical development and cancer","volume":"332","author":"El Wakil","year":"2011","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2015.03.001_bib129","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mce.2011.09.010","article-title":"Towards an understanding of the role of p53 in adrenocortical carcinogenesis","volume":"351","author":"Wasserman","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"10","key":"10.1016\/j.ecl.2015.03.001_bib130","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1210\/jc.2013-2165","article-title":"Molecular screening for a personalized treatment approach in advanced adrenocortical cancer","volume":"98","author":"De Martino","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.ecl.2015.03.001_bib131","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/jclinpath-2014-202514","article-title":"Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies","volume":"67","author":"Ross","year":"2014","journal-title":"J\u00a0Clin Pathol"}],"updated-by":[{"DOI":"10.1016\/j.ecl.2015.07.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000}}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852915000171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852915000171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T17:57:44Z","timestamp":1599069464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852915000171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":131,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0889852915000171"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2015.03.001","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adrenocortical Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2015.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}